Ja Hyang Cho

Ja Hyang Cho

Auto-generated profile, based on publicly available information

Ja Hyang Cho

Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JCJa Hyang Cho
Ja Hyang Cho
EKEungu Kang
Eungu Kang
BLBeom Hee Lee
Beom Hee Lee
GKGu-Hwan Kim
Gu-Hwan Kim
JCJin-Ho Choi
Jin-Ho Choi
HYHan-Wook Yoo
Han-Wook Yoo
Cho JH, et al. J Korean Med Sci. 2017 Jun;32(6):1042-1045. https://doi.org/10.3346/jkms.2017.32.6.1042

15 November 2024 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
JCJa Hyang Cho
Ja Hyang Cho
HJHae Woon Jung
Hae Woon Jung
KSKye Shik Shim
Kye Shik Shim
Height gains result from longitudinal bone growth, which is largely dependent on chondrocyte differentiation and proliferation within the growth plates of long bones. The growth plate, that is, the epiphyseal plate, is divided into resting, proliferative, and hypertrophic zones according to chondrocyte characteristics. The differentiation potential of progenitor cells in the resting zone, continuous capacity for chondrocyte differentiation and proliferation within the proliferative zone, timely replacement by osteocytes, and calcification in the hypertrophic zone are the 3 main factors controlling longitudinal bone growth. Upon adequate longitudinal bone growth, growth plate senescence limits human body height. During growth plate senescence, progenitor cells within the resting zone are depleted, proliferative chondrocyte numbers decrease, and hypertrophic chondrocyte number and size decrease. After senescence, hypertrophic chondrocytes are replaced by osteocytes, the extracellular matrix is calcified and vascularized, the growth plate is closed, and longitudinal bone growth is complete. To date, gonadotropin-releasing hormone analogs, aromatase inhibitors, C-type natriuretic peptide analogs, and fibroblast growth factor receptor 3 inhibitors have been studied or used as therapeutic interventions to delay growth plate closure. Complex networks of cellular, genetic, paracrine, and endocrine signals are involved in growth plate closure. However, the detailed mechanisms of this process remain unclear. Further elucidation of these mechanisms will enable the development of new therapeutic modalities for the treatment of short stature, precocious puberty, and skeletal dysplasia.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BKByung Ho Kang
Byung Ho Kang
JCJa Hyang Cho
Ja Hyang Cho
SKSo Youn Kim
So Youn Kim
KJKyoung A Jeong
Kyoung A Jeong
SKShin Hee Kim
Shin Hee Kim
KSKye Shik Shim
Kye Shik Shim
Kang BH, et al. J Korean Med Sci. 2020 Oct;35(45):e370. https://doi.org/10.3346/jkms.2020.35.e370

14 June 2023 in Journal of Obesity & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
JCJa Hyang Cho
Ja Hyang Cho
Ja Hyang Cho. J Obes Metab Syndr -0001;0:0-. https://doi.org/10.7570/jomes23025

31 December 2025 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
HWHyun Ah Woo
Hyun Ah Woo
JCJa Hyang Cho
Ja Hyang Cho
KSKye Shik Shim
Kye Shik Shim
DKDo Hyun Kim
Do Hyun Kim
HJHae Woon Jung
Hae Woon Jung
MHMi Young Han
Mi Young Han
Purpose: The increasing prevalence of type 2 diabetes (T2D) among adolescents and young adults (AYAs) is a major public health concern worldwide. This pilot study evaluated the effectiveness of lifestyle education in managing T2D in obese AYAs using continuous glucose monitoring (CGM) and smartwatch-derived lifelog data.Methods: Seven obese AYAs and T2D aged 12–19 years were enrolled in this prospective interventional study. Patients continued to take their previously prescribed T2D medication. CGM data were collected for 10 days, followed by lifestyle education using CGM and smartwatch data. Outcomes, including anthropometrics, glycemic control, dietary intake, physical activity, and self-management skills, were reassessed after an additional 10 days.Results: The median time in range increased from 58.1% (53.2%–75%) to 72% (64%–88%) (p=0.043) and time above range (>250 mg/dL) decreased from 10% (2.9%–18.6%) to 3.0% (1.0%–11.0%) (p=0.028). Median peak total caloric intake decreased from 2,854 (2,465–3,040) kcal/day to 2,091 (1,751–2,283) kcal/day and walking calorie expenditure increased from 163.9 (116.7–321.3) kcal/day to 180.2 (165.3–492.4) kcal/day (p=0.018 for both). The Summary of Diabetes Self-Care Activities score improved from 0.29 (0.05–0.43) to 0.33 (0.32–0.68) (p=0.043).Conclusion: This integrated approach combining CGM and smartwatch-based education exhibited short-term effects on glycemic control, dietary habits, physical activity, and self-management skills in obese AYAs and T2D. Further studies are needed to confirm the long-term effectiveness of this strategy in this challenging population.

20 March 2026 in Medicine
Verified
Journal Article
Open access
JCJa Hyang Cho
Ja Hyang Cho
KSKye Shik Shim
Kye Shik Shim
: Menarche significantly affects linear growth, and the extent of height gain after menarche remains a key clinical concern. This study aimed to analyze the relationship between menarche timing and pubertal height gain, determine the extent of height gain after menarche, and assess whether treatment is required in cases of early puberty with advanced bone age (BA). A retrospective chart review of 43 patients aged 12 to 16 years with precocious or early puberty was conducted between January and June 2022. Eight patients were excluded due to treatment with recombinant growth hormone. The remaining 35 patients were divided into 2 groups based on whether they received gonadotropin-releasing hormone (GnRH) agonists. Of the 35 patients, 27 (77.1%) were treated with GnRH agonists. The mean age at menarche was delayed (11.5 ± 1.0 vs 12.1 ± 1.7, respectively). The mean predicted adult height (PAH) before menarche was lower in the untreated than in the treated group (156.7 ± 1.8 and 160.0 ± 1.8 cm, respectively, P < .05) in the treated group. After menarche, mean PAH was 157.0 ± 0.7 cm in the untreated group and 160.5 ± 0.9 cm in the GnRH agonist group ( P = .04). Height gain after menarche was greater in the untreated group, 6.6 ± 3.9 versus 4.9 ± 3.0 cm, though it was not statistically significant. Importantly, the final height increase after menarche was negatively correlated with advanced BA before menarche ( r = −0.092, P < .001). The mean age at menarche was delayed in the GnRH agonist group, and the final PAH was higher than that in the untreated group. However, a later age at menarche was associated with lower pubertal height gain. An increase in PAH after treatment can be anticipated in patients with an advanced BA.